PfizerProjects record-breaking revenue by 2022. The company announced Tuesday that it plans to sell $32 Billion of Covid-19 shots, and $22 Billion of Paxlovid antiviral coronavirus treatment pills.

Based on Refinitiv’s average analyst estimates, here’s what the company did compared with Wall Street’s expectations.

• Adjusted EPS: $1.08 vs. 87 cents expected
• Revenue:$23.84 billion, compared to $24.12 billion anticipated

Pfizer began a trial of Covid late last month. vaccine that targets the omicron variantFor adults aged 18-55 years old. Albert Bourla, the CEO, stated that they expect to have the vaccine available by March.

PfizerAnd its partner BioNTechTo expedite the process, we also collaborate with Food and Drug Administration authorization of their Covid vaccine for children under 5-years-oldThe last person in the U.S. who isn’t eligible for vaccination was this month. Companies expect children below 5 years of age to need 3 doses. They are currently working to have the FDA approve two shots while trials continue on the third.

Pfizer also plans to increase production and deliver its Covid-treatment pill Paxlovid. Bourla stated that Pfizer anticipates producing 6 to 7 million to 120 million courses by the end this year. With 20 million orders already placed by the U.S., 10 million are expected to be delivered before June.

This is important breaking news. Stay tuned for new updates.